METAVAX® our proprietary platform to develop highly immunogenic chimeric VLP-based vaccines presenting customer’s antigen target. Our platform is built on the WHO recommended production host Hansenula polymorpha and our unique duck hepatitis B virus like particle (dHBs).

Download our METAVAX® brochure.

ARTES continuously develops valuable biosimilar processes. All of them excel with safe, fast and ef cient production features. Our cell lines and processes provide lower cost-of-goods and higher stability than originator and competitor processes. ARTES’ experienced technology transfer team is dedicated to support you for smooth implementation at your manufacturing site.

Download our BioSimilars brochure.

ARTES is a well-established R&D partner for the pharmaceutical industry. Our technology and know-how is secured by own IP, exclusive licenses and trade secrets. Our cell line development is based on efficient high-yield microbial expression platforms. Several recombinant products derived from our platforms are marketed worldwide by our clients.

Download our Development brochure.

Click here to add your own text

Withdraw from contract